Synergistic antitumor activity of oxaliplatin in combination with gemcitabine in pancreatic tumor-bearing mice

Chemotherapy

Volumn 53, Issue 3, 2007, Pages 153-159

  Moschidis, A ^a   Papageorgiou, A ^b   Atmatzidis, K ^c   Tsalis, K ^c   Moschidis, E ^c   Livanis, J ^c   Chrysogelou, E ^b   Mourelatos, D ^c   Tsavdaridis, D ^a   Harlaftis, N ^c  

^a 2nd IKA Hospital   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Gemcitabine; Oxaliplatin; Pancreatic ductal adenocarcinoma

Indexed keywords

GEMCITABINE; OXALIPLATIN;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER TRANSPLANTATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; FEMALE; LD 50; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG SYNERGISM; FEMALE; MALE; MICE; MICE, INBRED C57BL; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34147216920     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100513     Document Type: Article

References (21)

1. Raymond E, Faivre S, Woynarowsky J, et al: Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25(suppl 5):4-12.
2. Rixe O, Ortuzar W, Alvarez M, et al: Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug resistant cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem Pharmacol 1996;52:1855-1865.
3. Woynarowsky J, Chapman WG, Napier C, et al: Oxaliplatin effects on naked intracellular DNA (abstract A2083). Proc Am Assoc Cancer Res 1997;38:311.
4. Bleiberg H: Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 1998;77(suppl 4):1-3.
5. Cvitkovic E: Ongoing and unsaid on oxaliplatin: the hope. Br J Cancer 1998;77(suppl 4):8-11.
6. Huang P, Chubb S, Hertel L, Grindey GB, Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1999;51:6110-6117.
7. Hertel LW, Boder GB, et al: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990;50:4417-4422.
8. Boven E, Schipper H, Erkelens CAM, Harry SA, Prendo HM: The influence of the schedule and the dose of gemcitabine on the antitumor efficacy in experimental human cancer. Br J Cancer 1993;58:52-56.
9. Broachkis BJM, Van Dongen GMS, Vermorken JB, Snow GB: Preclinical in vivo activity of 2′-2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 1991;51:211-214.
10. Faivre S, Raymond E, Rixe O, et al: Preclinical synergy of oxaliplatin in combination with other antitumor agents (abstract 627). Ann Oncol 1998;9(suppl 4):131.
11. Goldin A, Sofina Z, Syrkin A: Experimental evaluation of antitumor drugs in USA and USSR and clinical correlations. Nat Cancer Inst Monogr 1980;55:37-39.
12. Nikolaropoulos S, Tsavdaridis D, Arsenou E, Papageorgiou A, Karaberis E, Mourelatos D: Synergistic antineoplastic and cytogenetic effects by the combined action of two homo-azasteroidal esters of nitrogen mustards on P388 and L1210 leukemias in vivo and in vitro. Anticancer Res 2000;20:2745-2752.
13. Huang H, Zhu L, Reld BR, Drobny GP, Hopkins PB: Solution structure of the cisplatin-induced DNA interstrand cross-link. Science 1995;270:1842-1844.
14. Ellerhorst JA, Frost P, Abruzzese JL, Newman A, Cheznajowsky Y: 2′-deoxy-5-azacytidine increase binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation. Br J Cancer 1992;67:209-215.
15. Abruzzese JL, Frost P: Studies on the mechanism of synergistic action between 2-deoxy-5-azacytidine and CDDP. Cancer Chemother Pharmacol 1992;30:31-36.
16. Plunkett W, Gandhi V, Chubb S, et al: 2′,2′- Difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleos Nucleot 1989;8:775-785.
17. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E: Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999;44:117-123.
18. Haller DG: Chemotherapy for advanced pancreatic cancer. Int J Radiat Oncol 2003;56:16-23.
19. Passeto LM: Old and new drugs in systemic therapy of pancreatic cancer. Crit Rev Oncol Hematol 2004;49:135-151.
20. Mylonaki-Charalambous E, Mourelatos D, Kotsis A: A comparative study of the cytogenetic and antineoplasmatic effects induced by carboplatin in combination with niacin in human lymphocytes in vitro and in Ehrlich ascites tumor cells in vivo. Chemotherapy 1998;44:121-128.
21. Papageorgiou A, Nikolaropoulos SS, Arsenou ES, Karaberis E, Mourelatos D, Kotsis A, Chryssogelou E: Enhanced cytogenetic and antineoplastic effects by the combined action of two esteric steroidal derivatives of nitrogen mustards. Chemotherapy 1999;45:61-67.